Gel vs. injection TRT: Are subcutaneous shots really more stable?

What did @neos_clinica actually say?

Here is the uncomfortable part: the transcript provided for this video contains no actual medical claims. The words captured are "I think the world has been and we will see you in the next video" repeated twice. That is not a medical explanation. That is a recording artifact, a cut-off clip, or a caption mismatch.

What the caption does claim is worth examining on its own, because it is making real clinical arguments. The caption states that gel absorption varies by individual, that subcutaneous injections produce "much more stable levels," and implies that specialists prefer injections for this reason. Those are specific, checkable claims, and they deserve a proper look even if the audio failed to deliver them.

Does the science back this up?

Partially, yes. The absorption variability claim for testosterone gel is well-documented and not controversial. The "much more stable levels" claim for subcutaneous injections compared to gel is more nuanced than the caption suggests.

Gel absorption does vary significantly between individuals. Testosterone transfer to partners and children through skin contact is a documented safety concern noted by the FDA. A study by Steidle et al. (2003, Journal of Clinical Endocrinology and Metabolism) confirmed meaningful inter-individual variability in serum levels with transdermal testosterone.

On the injection side, subcutaneous testosterone cypionate has been studied specifically for its pharmacokinetic profile. Spratt et al. (2017, Journal of Clinical Endocrinology and Metabolism) found that subcutaneous injections produced lower peak-to-trough fluctuations compared to intramuscular injections at equivalent doses. However, comparing subcutaneous injections directly to daily transdermal gels is more complicated. Daily gel application actually mimics physiological rhythm reasonably well in compliant patients. The claim that subcutaneous injections are categorically more stable than gel is an oversimplification.

What did they get wrong (or right)?

They got the absorption variability point right. Skin absorption of testosterone is genuinely inconsistent across patients. Factors including skin hydration, application site, sweating, and showering timing all affect delivery. This is a real clinical limitation of gel formulations, not a marketing talking point.

Where the caption overshoots is in calling subcutaneous injection levels "much more stable" as a blanket statement. Stability depends heavily on injection frequency. Weekly subcutaneous injections still produce measurable peaks and troughs. Twice-weekly or every-three-day subcutaneous protocols do flatten the curve considerably, but that nuance is absent here.

The caption also implies a specialist consensus favoring injections. That framing is selective. Many endocrinologists and urologists still prescribe gel as a first-line option, particularly for patients where injection adherence is a concern. Neither modality is universally superior. The Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) treat both as valid options with different risk and adherence profiles, not a clear hierarchy.

What should you actually know?

The delivery method debate in TRT is real and clinically relevant, but it is not as one-sided as this caption implies. Here is what the evidence actually supports.

Subcutaneous testosterone at frequent intervals (two or three times per week) does produce more consistent serum levels than weekly intramuscular injections. That part holds up. But comparing it favorably to daily gel use is a harder argument to make without specifying frequency and patient compliance.

Gel carries genuine risks beyond absorption variability, including secondary exposure to household contacts, which is a documented concern in pediatric cases. That is a legitimate reason some clinicians steer patients toward injections.

Individual patient factors matter more than any general ranking. A patient who applies gel correctly at the same time daily on clean dry skin will often have predictable levels. A patient doing infrequent subcutaneous injections with poor technique may have worse outcomes than a compliant gel user.

If you are on TRT through a supervised platform and wondering which delivery method suits your situation, that conversation belongs with your prescriber, not a 60-second social video.